Long-acting injectable ART (Cabenuva) offers a promising solution to persistent adherence challenges among people with HIV, particularly those facing housing instability, stigma, or pill fatigue. This mixed-methods cohort study compares adherence and viral suppression between patients on Cabenuva and those on daily oral ART at Heather Ivy, a Ryan White-funded HIV clinic. We reviewed medical records, pharmacy data, and laboratory results to assess quantitative outcomes and administered patient and provider surveys to explore barriers and facilitators of adherence.

Preliminary findings suggest Cabenuva patients have higher adherence rates and comparable or improved viral suppression, with many citing convenience and reduced stigma as major benefits. However, logistical issues such as missed injection windows and insurance hurdles remain significant. Provider responses reveal both enthusiasm and practical concerns regarding workflow integration and patient eligibility.

This study highlights Cabenuva’s potential to reduce adherence gaps and improve outcomes in structurally marginalized populations. The findings support further implementation of long-acting regimens and may inform policies aimed at increasing treatment access and equity in HIV care.